[go: up one dir, main page]

AR018147A1 - Una forma de dosificacion y de liberacion controlada que contiene monohidrocloruro de [r-(z)]-alfa-(metoxiimino)-alfa-(1-azabiciclo[2,2,2]oct-3-il)acetonitrilo, un procedimiento para su preparacion, una composicion farmaceutica que comprende dicha forma de dosificacion, la utilizacion de dicha forma - Google Patents

Una forma de dosificacion y de liberacion controlada que contiene monohidrocloruro de [r-(z)]-alfa-(metoxiimino)-alfa-(1-azabiciclo[2,2,2]oct-3-il)acetonitrilo, un procedimiento para su preparacion, una composicion farmaceutica que comprende dicha forma de dosificacion, la utilizacion de dicha forma

Info

Publication number
AR018147A1
AR018147A1 ARP990100991A ARP990100991A AR018147A1 AR 018147 A1 AR018147 A1 AR 018147A1 AR P990100991 A ARP990100991 A AR P990100991A AR P990100991 A ARP990100991 A AR P990100991A AR 018147 A1 AR018147 A1 AR 018147A1
Authority
AR
Argentina
Prior art keywords
alpha
dosage
oct
aqueous dispersion
acetonitrile
Prior art date
Application number
ARP990100991A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805192.3A external-priority patent/GB9805192D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of AR018147A1 publication Critical patent/AR018147A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)

Abstract

Una forma de dosificacion oral y de liberacion controlada, que contiene monohidrocloruro de [R-(Z)]-alfa-(metoxiimino)-alfa-(1-azabiciclo[2,2,2]oct-3-il)acetonitrilo (compuesto X) caracterizado porque comprende la composicion de Tabla (I) comprimidaen tabletas y revestida hasta una ganancia de peso de 3% conuna solucion de revestimiento de sellado que consiste en una dispersion acuosa de dihidrometilcelulosa con plastificante en agua purificada a una concentracionde solidos de 10%, seguida deu na capa que consiste en una dispersion acuosa de etilcelulosa con ácido oleico, dihidroxido de amonio y plastificante o unamezcla de dispersion acuosa de etilcelulosa con ácido oleico hidroxido de amonio y una dispersion acuosa dehidroxipropilmetilc elulosa con plastificante,utiles en el tratamiento y la profilaxis de demencia, incluyendo enfermedad de Alzheimer, en mamíferos, y/o para realzar la maduracion de la proteínaprecursora amiloidea a lo largo de una ruta noamoloidogena en pacientes q ue padecen enfermedad de Alzheimer o están en una situacion de riesgo dedesarrollarla, una forma de dosificacion y de liberacion controlada que contiene monohidrocloruro de[R-(Z)]-alfa-(metoxiimido)-alfa-(1-azabiciclo[2,2,2]oct-3-il)acetonitrilo, un procedimiento para su preparacion, una composicion farmacéutica que comprende dicha forma de dosificacion, la utilizacion de dicha forma dedosificacion para la fabricacionde un medicamento.
ARP990100991A 1998-03-11 1999-03-09 Una forma de dosificacion y de liberacion controlada que contiene monohidrocloruro de [r-(z)]-alfa-(metoxiimino)-alfa-(1-azabiciclo[2,2,2]oct-3-il)acetonitrilo, un procedimiento para su preparacion, una composicion farmaceutica que comprende dicha forma de dosificacion, la utilizacion de dicha forma AR018147A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7752798P 1998-03-11 1998-03-11
US7748098P 1998-03-11 1998-03-11
GBGB9805192.3A GB9805192D0 (en) 1998-03-11 1998-03-11 Composition

Publications (1)

Publication Number Publication Date
AR018147A1 true AR018147A1 (es) 2001-10-31

Family

ID=27269240

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100991A AR018147A1 (es) 1998-03-11 1999-03-09 Una forma de dosificacion y de liberacion controlada que contiene monohidrocloruro de [r-(z)]-alfa-(metoxiimino)-alfa-(1-azabiciclo[2,2,2]oct-3-il)acetonitrilo, un procedimiento para su preparacion, una composicion farmaceutica que comprende dicha forma de dosificacion, la utilizacion de dicha forma

Country Status (16)

Country Link
US (1) US6451343B1 (es)
EP (1) EP1061918A1 (es)
JP (1) JP2002506031A (es)
KR (1) KR20010034588A (es)
CN (1) CN1292696A (es)
AR (1) AR018147A1 (es)
AU (1) AU748396C (es)
CA (1) CA2323177A1 (es)
CO (1) CO5080740A1 (es)
HU (1) HUP0101043A3 (es)
IL (1) IL138192A0 (es)
NO (1) NO20004491L (es)
NZ (1) NZ505807A (es)
PL (1) PL342600A1 (es)
TR (1) TR200002626T2 (es)
WO (1) WO1999045924A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2813651B1 (fr) 2000-09-05 2004-06-11 Valeo Appareil d'accouplement hydrocinetique, notamment pour vehicule automobile
JP2005516020A (ja) * 2001-12-20 2005-06-02 ファルマシア・コーポレーション ゼロ次持続放出剤形およびその製造方法
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040683A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina
US8679533B2 (en) * 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
EP2431027A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2736965C (en) 2004-08-13 2014-02-18 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
JP2009526021A (ja) * 2006-02-10 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 放出を加減した製剤
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
WO2012027558A2 (en) * 2010-08-25 2012-03-01 The Trustees Of Columbia University In The City Of New York OPTIMIZED miRNA CONSTRUCTS
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) * 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
US11648242B2 (en) * 2019-12-12 2023-05-16 Aurobindo Pharma Ltd Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207444B (en) 1990-07-12 1993-04-28 Biorex Kutato Fejlesztoe Kft Method for producing therapeutical preparation suitable for treating alzheimer-disease
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
GB9421472D0 (en) 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition

Also Published As

Publication number Publication date
KR20010034588A (ko) 2001-04-25
CN1292696A (zh) 2001-04-25
HUP0101043A3 (en) 2002-02-28
JP2002506031A (ja) 2002-02-26
AU748396C (en) 2003-01-23
HUP0101043A2 (hu) 2001-12-28
US6451343B1 (en) 2002-09-17
AU3033299A (en) 1999-09-27
NO20004491D0 (no) 2000-09-08
NO20004491L (no) 2000-09-08
PL342600A1 (en) 2001-06-18
CO5080740A1 (es) 2001-09-25
TR200002626T2 (tr) 2001-03-21
EP1061918A1 (en) 2000-12-27
CA2323177A1 (en) 1999-09-16
IL138192A0 (en) 2001-11-25
AU748396B2 (en) 2002-06-06
NZ505807A (en) 2003-01-31
WO1999045924A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
AR018147A1 (es) Una forma de dosificacion y de liberacion controlada que contiene monohidrocloruro de [r-(z)]-alfa-(metoxiimino)-alfa-(1-azabiciclo[2,2,2]oct-3-il)acetonitrilo, un procedimiento para su preparacion, una composicion farmaceutica que comprende dicha forma de dosificacion, la utilizacion de dicha forma
BR0116605A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
HUP0302571A2 (hu) Szerves vegyületek keverékét tartalmazó gyógyszerkészítmény légúti betegségek kezelésére
MX9404762A (es) Composiciones para inhalacion y proceso para su preparacion.
BR0112918A (pt) Composto, utilização do mesmo, processo de tratamento de distúrbios, processo para a preparação de composto, composição farmacêutica que compreende esse composto, processo para preparar uma composição e processo de tratamento de obesidade em um ser humano
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BG104620A (en) Oral pharmaceutical extended release dosage form
HUP0203728A2 (hu) Formoterolt tartalmazó aeroszolkészítmény
BR0208382A (pt) Forma de dosagem oral contendo nicotina
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
NO992907L (no) Flat legemiddeltilberedning for applikasjon og frigiving av buprenorfin eller et annet farmakologisk sammenlignbart stoff i munnhulen og fremgangsmÕte for dens fremstilling
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
WO2001047913A3 (de) Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung
NO179995C (no) Fremgangsmåte for fremstilling av legemiddel-lipidsystemer med lav toksisitet inneholdende polyen-antibiotika
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
BR9913102A (pt) Composto, produtos contento um composto, processo para preparação de um composto, formulação farmacêutica contento um composto, uso de um composto, processos para inibir a secreção de ácido gástrico, para o tratamento de doenças inflamatórias gastrintestinais e, para o tratamento ou profilaxia de condições que envolvam a infecção por helicobacter pylori da mucosa gástrica humana, e, formulação farmacêutica
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
DE3269241D1 (en) Triazoloquinazolines, process for their preparation and pharmaceutical compositions containing them
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
ECSP003538A (es) Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2.] oct-3-ilamina y sus composiciones farmaceuticas
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
ECSP003508A (es) Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas
AU3843195A (en) Use of R-(Z) -alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2 oct-3-yl) acetonitrile to reduce amyloid beta A4 formation in Alzheimer's disease

Legal Events

Date Code Title Description
FB Suspension of granting procedure